Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Рациональный выбор комбинированной антигипертензивной терапии
Рациональный выбор комбинированной антигипертензивной терапии
Морозова Т.Е., Гонтаренко С.В. Рациональный выбор комбинированной антигипертензивной терапии. Consilium Medicum. 2016; 18 (1): 10–15. DOI: 10.26442/2075-1753_2016.1.10-15
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В обзоре представлены данные, касающиеся оптимизации фармакотерапии артериальной гипертонии с целью снижения риска сердечно-сосудистых заболеваний и их осложнений фиксированными комбинациями антигипертензивных лекарственных средств на основе применения фиксированной комбинации периндоприла и индапамида.
Ключевые слова: сердечно-сосудистые заболевания, сердечно-сосудистый риск, артериальная гипертензия, фармакотерапия, ингибиторы ангиотензинпревращающего фермента, диуретики, периндоприл, индапамид, комбинированная терапия, фиксированные комбинации.
Key words: cardiovascular disease, cardiovascular risk, arterial hypertension, pharmacotherapy, angiotensin-converting enzyme inhibitors, diuretics, perindopril, indapamide combination therapy, fixed combination.
Ключевые слова: сердечно-сосудистые заболевания, сердечно-сосудистый риск, артериальная гипертензия, фармакотерапия, ингибиторы ангиотензинпревращающего фермента, диуретики, периндоприл, индапамид, комбинированная терапия, фиксированные комбинации.
________________________________________________
Key words: cardiovascular disease, cardiovascular risk, arterial hypertension, pharmacotherapy, angiotensin-converting enzyme inhibitors, diuretics, perindopril, indapamide combination therapy, fixed combination.
Полный текст
Список литературы
1. Клинические рекомендации «Диагностика и лечение артериальной гипертонии». 2013. http://www.cardioweb.ru/klinicheskie-rekomendatsii / Klinicheskie rekomendatsii «Diagnostika i lechenie arterial'noi gipertonii». 2013. http://www.cardioweb.ru/klinicheskie-rekomendatsii [in Russian]
2. Диагностика и лечение артериальной гипертензии. Российские рекомендации ВНОК/РМОАГ (четвертый пересмотр). Системные гипертензии. 2010; 7 (3). / Recommendations for the management of arterial hypertension Russian Medical Society of Arterial Hypertension and Society of Cardiology of the Russian Federation. Systemic Hypertension. 2010; 7 (3). [in Russian]
3. ESH/ESC Guidelines for themanagement of arterial hypertension. J Hypertens 2013; 31: 1281–357.
4. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
5. Wald DS et al. Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials. Am J Med 2009; 122 (3): 290.
6. Леонова М.В., Белоусов Д.Ю., Штейнберг Л.Л. и аналитическая группа исследования ПИФАГОР. Анализ врачебной практики проведения антигипертензивной терапии в России (по данным исследования ПИФАГОР III). Фарматека. 2009; 2: 98–103. / Leonova M.V., Belousov D.Iu., Shteinberg L.L. i analiticheskaia gruppa issledovaniia PIFAGOR. Analiz vrachebnoi praktiki provedeniia antigipertenzivnoi terapii v Rossii (po dannym issledovaniia PIFAGOR III). Farmateka. 2009; 2: 98–103. [in Russian]
7. The PROGRESS Collaborative Group. Randomised trial of aperindopril-based blood-pressure-lowering among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
8. The EUROPA investigators. Efficacy of perindopril in reduction ofcardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentertrial (the EUROPA study). Lancet 2003; 362: 782–8.
9. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascularevents with an antihypertensive regimen of amlodipine adding perindopril as required vs. atenolol adding bendroflumethiazide asrequired, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
10. Beckett NS, Peters R, Fletcher AE et al for the HYVET Study Group. Treatment of hypertension in patients 80 years of age and older. NEJM 2008; 358: 1887–98.
11. ADVANCE Collaborative Group. Effects of fixed combination ofperindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial):a randomised controlled trial. Lancet 2007; 370: 828–40.
12. Vark van LC, Bertrand M, Akkerhuis KM et al. Angiotensin-convertingenzyme inhibitors reduce mortality in hypertension: a metaanalysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012; 33 (16): 2088–97.
13. Романенко В.В., Романенко З.В. Ингибиторы АПФ – препараты первой линии в лечении сердечно-сосудистых заболеваний. Международные обзоры: клиническая практика и здоровье. 2014; 3 (9): 5–25. / Romanenko V.V., Romanenko Z.V. Ingibitory APF – preparaty pervoi linii v lechenii serdechno-sosudistykh zabolevanii. Mezhdunarodnye obzory: klinicheskaia praktika i zdorov'e. 2014; 3 (9): 5–25. [in Russian]
14. Brugts JJ, Arima H, Remme W et al. The Incidence and Clinical predictors of ACE inhibitor Induced Dry Cough by Perindopril in 27.492 Patients with Vascular Disease: A Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS-trials comparing a perindopril-treatment regimen versus placebo. Int J Cardiol 2014. Doi: 10.1016/j.ijcard. 2014.07.108.
15. Daly CA, Fox KM, Remme WJ. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26: 1369–78.
16. Dufouil C, Chalmers J, Coskun O. Effects of blood pressure lowering of cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112 (11): 1644–50.
17. Мычка В.Б., Жернакова Ю.В., Чазова И.Е. Улучшенная форма Периндоприла – пРЕстариуМА в лечении больных артерИальной гипертонией в разных клинических ситуациЯх (ПРЕМИЯ). Системные гипертензии. 2009; 6 (4): 50–3. / Mychka V.B., Zhernakova Yu.V., Chazova I.E. The improved form perindopril in treatment of arterial hypertension in various clinical situations (PREMIA). Systemic Hypertension. 2009; 6 (4): 50–3. [in Russian]
18. Морозова Т.Е., Латыйпова Е.Р. Больной АГ с ожирением: влияние на биомаркеры как инструмент персонализированного подхода к терапии. Рос. кардиол. журн. 2013; 3 (101): 94–9. / Morozova T.E., Latyipova E.R. Bol'noi AG s ozhireniem: vliianie na biomarkery kak instrument personalizirovannogo podkhoda k terapii. Ros. kardiol. zhurn. 2013; 3 (101): 94–9. [in Russian]
19. Морозова Т.Е., Гонтаренко С.В. Влияние антигипертензивных препаратов на состояние когнитивных функций у больных артериальной гипертензией I–II степени. Лечащий врач. 2014; 7: 15–20. / Morozova T.E., Gontarenko S.V. Vliianie antigipertenzivnykh preparatov na sostoianie kognitivnykh funktsii u bol'nykh arterial'noi gipertenziei I–II stepeni. Lechashchii vrach. 2014; 7: 15–20. [in Russian]
20. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association. American Stroke Association. Stroke 2011; 42: 227–76.
21. Nice guidelines. Management of hypertension in adults in primary care. Update of clinical guidelines 18 and 34, 2011. http://www.nice.org.uk
22. Leonetti G, Rappelli A, Salvetti A et al. Long-term effects of indapamide: final results of a two-year Italian multicenter study in systemic hypertension. Am J Cardiol 1990; 65: 67–71.
23. Harrower A, McFarlane G, Donnelly T et al. Effect of indapamide on blood pressure and glucose tolerance in non-insulin-dependent diabetes. Hypertension 1985; 7 (Suppl. II): 161–3.
24. Mironneau J. Indapamide-induced inhibition of calcium movement in smooth muscles. Am J Med 1988; 84 (Suppl. IB): 10–4.
25. Schini VB, Dewey J, Vanhoutte PM. Related effects of indapamide on endothelium – dependent relaxations in isolated canine femoral arteries. Am J Cardiol 1990; 65: H6–10.
26. Gosse PH, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus Enalapril 20 mg: LIVE study. J Hypertens 2000; 18: 1465–75.
27. Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study. Vasc Health Risk Manag 2008; 4 (2): 443–51.
28. Pella D. Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg: results of the FALCO FORTE programme. High Blood Press Cardiovasc Prev 2011; 18 (3): 107–13.
29. Dahlof B, Grosse P, Gueret P et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PIXEL study. J Hypertension 2005; 23: 2063–70.
30. Mogensen CE, Viberti G, Halimi S et al. Preterax in Albuminuria Regression (PREMIER) Study Groupe. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Preterax in Albuminuria Regression: PREMIER. Hypertension 2003; 41: 1063–71.
31. Zoungas S et al. Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. N Engl J Med. Doi: 10.1056/NEJMoa1407963.
32. Чазова И., Ратова Л., Мартынюк Т. от имени коллектива авторов. Итоги Российского исследования СТРАТЕГИЯ А (Российская многоцентровая программа по оценке эффективности Нолипрела А Форте у пациентов с артериальной гипертонией высокого риска с недостаточным контролем артериального давления). Consilium Medicum. 2012; 14 (1): 5–12. / Chazova I., Ratova L., Martyniuk T. ot imeni kollektiva avtorov. Itogi Rossiiskogo issledovaniia STRATEGIIa A (Rossiiskaia mnogotsentrovaia programma po otsenke effektivnosti Noliprela A Forte u patsientov s arterial'noi gipertoniei vysokogo riska s nedostatochnym kontrolem arterial'nogo davleniia). Consilium Medicum. 2012; 14 (1): 5–12. [in Russian]
33. Маньковский Б.Н., Иванов Д.Д. Влияние антигипертензивной терапии на функцию почек у больных сахарным диабетом 2 типа: результаты проспективного исследования СКИФ-2. ProCardio 2010; 8 (144): 28–32. / Man'kovskii B.N., Ivanov D.D. Vliianie antigipertenzivnoi terapii na funktsiiu pochek u bol'nykh sakharnym diabetom 2 tipa: rezul'taty prospektivnogo issledovaniia SKIF-2. ProCardio 2010; 8 (144): 28–32. [in Russian]
34. Сиренко Ю.Н., Маньковский Б.Н., Радченко А.Д., Кушнир С.Н. от имени участников исследования. Результаты проспективного открытого исследования по оценке антигипертензивной эффективности и переносимости нолипрела би-форте у пациентов с неконтролируемой артериальной гипертензией и сахарным диабетом 2-го типа (исследованиe практик). Артериальная гипертензия. 2012; 4 (24): 9–23. / Sirenko Iu.N., Man'kovskii B.N., Radchenko A.D., Kushnir S.N. ot imeni uchastnikov issledovaniia. Rezul'taty prospektivnogo otkrytogo issledovaniia po otsenke antigipertenzivnoi effektivnosti i perenosimosti noliprela bi-forte u patsientov s nekontroliruemoi arterial'noi gipertenziei i sakharnym diabetom 2-go tipa (issledovanie praktik). Arterial'naia gipertenziia. 2012; 4 (24): 9–23. [in Russian]
35. De Galan BE, Perkovic V, Ninomiya T et al. On behalfof the ADVANCE Collaborativе Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrology 2009. Doi: 10.1681/ASN.2008070667.9, 20.
36. Ruilope LM, Mancia G, Chalmers J. Does use of antihypertensive treatment to reduce albuminuria translate into effective benefits on outcome and mortality? A reappraisal of studies with renal endpoints in diabetes. J Hypertens 2010; 28. Doi: 10.1097/01.hjh.0000379031.35224.c0.
37. Глезер М.Г., Авакян А.А. Эффективность и безопасность терапии полнодозовой комбинацией периндоприла А/индапамида (10/2,5 мг) у пациентов с артериальной гипертонией. Кардиоваск. профилактика и терапия. 2012; 5: 4–11. / Glezer M.G., Avakian A.A. Effektivnost' i bezopasnost' terapii polnodozovoi kombinatsiei perindoprila A/indapamida (10/2,5 mg) u patsientov s arterial'noi gipertoniei. Kardiovask. profilaktika i terapiia. 2012; 5: 4–11. [in Russian]
38. Карпов Ю.А. Программа ФОРТИССИМО: преимущества фиксированной полнодозовой комбинации периндоприла аргинина и индапамида в лечении плохо контролируемой артериальной гипертонии от имени участников программы ФОРТИССИМО. Кардиология. 2013; 3: 37–43. / Karpov Iu.A. Programma FORTISSIMO: preimushchestva fiksirovannoi polnodozovoi kombinatsii perindoprila arginina i indapamida v lechenii plokho kontroliruemoi arterial'noi gipertonii ot imeni uchastnikov programmy FORTISSIMO. Kardiologiia. 2013; 3: 37–43. [in Russian]
2. Recommendations for the management of arterial hypertension Russian Medical Society of Arterial Hypertension and Society of Cardiology of the Russian Federation. Systemic Hypertension. 2010; 7 (3). [in Russian]
3. ESH/ESC Guidelines for themanagement of arterial hypertension. J Hypertens 2013; 31: 1281–357.
4. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
5. Wald DS et al. Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials. Am J Med 2009; 122 (3): 290.
6. Leonova M.V., Belousov D.Iu., Shteinberg L.L. i analiticheskaia gruppa issledovaniia PIFAGOR. Analiz vrachebnoi praktiki provedeniia antigipertenzivnoi terapii v Rossii (po dannym issledovaniia PIFAGOR III). Farmateka. 2009; 2: 98–103. [in Russian]
7. The PROGRESS Collaborative Group. Randomised trial of aperindopril-based blood-pressure-lowering among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
8. The EUROPA investigators. Efficacy of perindopril in reduction ofcardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentertrial (the EUROPA study). Lancet 2003; 362: 782–8.
9. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascularevents with an antihypertensive regimen of amlodipine adding perindopril as required vs. atenolol adding bendroflumethiazide asrequired, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
10. Beckett NS, Peters R, Fletcher AE et al for the HYVET Study Group. Treatment of hypertension in patients 80 years of age and older. NEJM 2008; 358: 1887–98.
11. ADVANCE Collaborative Group. Effects of fixed combination ofperindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial):a randomised controlled trial. Lancet 2007; 370: 828–40.
12. Vark van LC, Bertrand M, Akkerhuis KM et al. Angiotensin-convertingenzyme inhibitors reduce mortality in hypertension: a metaanalysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012; 33 (16): 2088–97.
13. Romanenko V.V., Romanenko Z.V. Ingibitory APF – preparaty pervoi linii v lechenii serdechno-sosudistykh zabolevanii. Mezhdunarodnye obzory: klinicheskaia praktika i zdorov'e. 2014; 3 (9): 5–25. [in Russian]
14. Brugts JJ, Arima H, Remme W et al. The Incidence and Clinical predictors of ACE inhibitor Induced Dry Cough by Perindopril in 27.492 Patients with Vascular Disease: A Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS-trials comparing a perindopril-treatment regimen versus placebo. Int J Cardiol 2014. Doi: 10.1016/j.ijcard. 2014.07.108.
15. Daly CA, Fox KM, Remme WJ. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26: 1369–78.
16. Dufouil C, Chalmers J, Coskun O. Effects of blood pressure lowering of cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112 (11): 1644–50.
17. Mychka V.B., Zhernakova Yu.V., Chazova I.E. The improved form perindopril in treatment of arterial hypertension in various clinical situations (PREMIA). Systemic Hypertension. 2009; 6 (4): 50–3. [in Russian]
18. Morozova T.E., Latyipova E.R. Bol'noi AG s ozhireniem: vliianie na biomarkery kak instrument personalizirovannogo podkhoda k terapii. Ros. kardiol. zhurn. 2013; 3 (101): 94–9. [in Russian]
19. Morozova T.E., Gontarenko S.V. Vliianie antigipertenzivnykh preparatov na sostoianie kognitivnykh funktsii u bol'nykh arterial'noi gipertenziei I–II stepeni. Lechashchii vrach. 2014; 7: 15–20. [in Russian]
20. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association. American Stroke Association. Stroke 2011; 42: 227–76.
21. Nice guidelines. Management of hypertension in adults in primary care. Update of clinical guidelines 18 and 34, 2011. http://www.nice.org.uk
22. Leonetti G, Rappelli A, Salvetti A et al. Long-term effects of indapamide: final results of a two-year Italian multicenter study in systemic hypertension. Am J Cardiol 1990; 65: 67–71.
23. Harrower A, McFarlane G, Donnelly T et al. Effect of indapamide on blood pressure and glucose tolerance in non-insulin-dependent diabetes. Hypertension 1985; 7 (Suppl. II): 161–3.
24. Mironneau J. Indapamide-induced inhibition of calcium movement in smooth muscles. Am J Med 1988; 84 (Suppl. IB): 10–4.
25. Schini VB, Dewey J, Vanhoutte PM. Related effects of indapamide on endothelium – dependent relaxations in isolated canine femoral arteries. Am J Cardiol 1990; 65: H6–10.
26. Gosse PH, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus Enalapril 20 mg: LIVE study. J Hypertens 2000; 18: 1465–75.
27. Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study. Vasc Health Risk Manag 2008; 4 (2): 443–51.
28. Pella D. Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg: results of the FALCO FORTE programme. High Blood Press Cardiovasc Prev 2011; 18 (3): 107–13.
29. Dahlof B, Grosse P, Gueret P et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PIXEL study. J Hypertension 2005; 23: 2063–70.
30. Mogensen CE, Viberti G, Halimi S et al. Preterax in Albuminuria Regression (PREMIER) Study Groupe. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Preterax in Albuminuria Regression: PREMIER. Hypertension 2003; 41: 1063–71.
31. Zoungas S et al. Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. N Engl J Med. Doi: 10.1056/NEJMoa1407963.
32. Chazova I., Ratova L., Martyniuk T. ot imeni kollektiva avtorov. Itogi Rossiiskogo issledovaniia STRATEGIIa A (Rossiiskaia mnogotsentrovaia programma po otsenke effektivnosti Noliprela A Forte u patsientov s arterial'noi gipertoniei vysokogo riska s nedostatochnym kontrolem arterial'nogo davleniia). Consilium Medicum. 2012; 14 (1): 5–12. [in Russian]
33. Man'kovskii B.N., Ivanov D.D. Vliianie antigipertenzivnoi terapii na funktsiiu pochek u bol'nykh sakharnym diabetom 2 tipa: rezul'taty prospektivnogo issledovaniia SKIF-2. ProCardio 2010; 8 (144): 28–32. [in Russian]
34. Sirenko Iu.N., Man'kovskii B.N., Radchenko A.D., Kushnir S.N. ot imeni uchastnikov issledovaniia. Rezul'taty prospektivnogo otkrytogo issledovaniia po otsenke antigipertenzivnoi effektivnosti i perenosimosti noliprela bi-forte u patsientov s nekontroliruemoi arterial'noi gipertenziei i sakharnym diabetom 2-go tipa (issledovanie praktik). Arterial'naia gipertenziia. 2012; 4 (24): 9–23. [in Russian]
35. De Galan BE, Perkovic V, Ninomiya T et al. On behalfof the ADVANCE Collaborativе Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrology 2009. Doi: 10.1681/ASN.2008070667.9, 20.
36. Ruilope LM, Mancia G, Chalmers J. Does use of antihypertensive treatment to reduce albuminuria translate into effective benefits on outcome and mortality? A reappraisal of studies with renal endpoints in diabetes. J Hypertens 2010; 28. Doi: 10.1097/01.hjh.0000379031.35224.c0.
37. Glezer M.G., Avakian A.A. Effektivnost' i bezopasnost' terapii polnodozovoi kombinatsiei perindoprila A/indapamida (10/2,5 mg) u patsientov s arterial'noi gipertoniei. Kardiovask. profilaktika i terapiia. 2012; 5: 4–11. [in Russian]
38. Karpov Iu.A. Programma FORTISSIMO: preimushchestva fiksirovannoi polnodozovoi kombinatsii perindoprila arginina i indapamida v lechenii plokho kontroliruemoi arterial'noi gipertonii ot imeni uchastnikov programmy FORTISSIMO. Kardiologiia. 2013; 3: 37–43. [in Russian]
2. Диагностика и лечение артериальной гипертензии. Российские рекомендации ВНОК/РМОАГ (четвертый пересмотр). Системные гипертензии. 2010; 7 (3). / Recommendations for the management of arterial hypertension Russian Medical Society of Arterial Hypertension and Society of Cardiology of the Russian Federation. Systemic Hypertension. 2010; 7 (3). [in Russian]
3. ESH/ESC Guidelines for themanagement of arterial hypertension. J Hypertens 2013; 31: 1281–357.
4. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
5. Wald DS et al. Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials. Am J Med 2009; 122 (3): 290.
6. Леонова М.В., Белоусов Д.Ю., Штейнберг Л.Л. и аналитическая группа исследования ПИФАГОР. Анализ врачебной практики проведения антигипертензивной терапии в России (по данным исследования ПИФАГОР III). Фарматека. 2009; 2: 98–103. / Leonova M.V., Belousov D.Iu., Shteinberg L.L. i analiticheskaia gruppa issledovaniia PIFAGOR. Analiz vrachebnoi praktiki provedeniia antigipertenzivnoi terapii v Rossii (po dannym issledovaniia PIFAGOR III). Farmateka. 2009; 2: 98–103. [in Russian]
7. The PROGRESS Collaborative Group. Randomised trial of aperindopril-based blood-pressure-lowering among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
8. The EUROPA investigators. Efficacy of perindopril in reduction ofcardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentertrial (the EUROPA study). Lancet 2003; 362: 782–8.
9. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascularevents with an antihypertensive regimen of amlodipine adding perindopril as required vs. atenolol adding bendroflumethiazide asrequired, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
10. Beckett NS, Peters R, Fletcher AE et al for the HYVET Study Group. Treatment of hypertension in patients 80 years of age and older. NEJM 2008; 358: 1887–98.
11. ADVANCE Collaborative Group. Effects of fixed combination ofperindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial):a randomised controlled trial. Lancet 2007; 370: 828–40.
12. Vark van LC, Bertrand M, Akkerhuis KM et al. Angiotensin-convertingenzyme inhibitors reduce mortality in hypertension: a metaanalysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012; 33 (16): 2088–97.
13. Романенко В.В., Романенко З.В. Ингибиторы АПФ – препараты первой линии в лечении сердечно-сосудистых заболеваний. Международные обзоры: клиническая практика и здоровье. 2014; 3 (9): 5–25. / Romanenko V.V., Romanenko Z.V. Ingibitory APF – preparaty pervoi linii v lechenii serdechno-sosudistykh zabolevanii. Mezhdunarodnye obzory: klinicheskaia praktika i zdorov'e. 2014; 3 (9): 5–25. [in Russian]
14. Brugts JJ, Arima H, Remme W et al. The Incidence and Clinical predictors of ACE inhibitor Induced Dry Cough by Perindopril in 27.492 Patients with Vascular Disease: A Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS-trials comparing a perindopril-treatment regimen versus placebo. Int J Cardiol 2014. Doi: 10.1016/j.ijcard. 2014.07.108.
15. Daly CA, Fox KM, Remme WJ. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26: 1369–78.
16. Dufouil C, Chalmers J, Coskun O. Effects of blood pressure lowering of cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112 (11): 1644–50.
17. Мычка В.Б., Жернакова Ю.В., Чазова И.Е. Улучшенная форма Периндоприла – пРЕстариуМА в лечении больных артерИальной гипертонией в разных клинических ситуациЯх (ПРЕМИЯ). Системные гипертензии. 2009; 6 (4): 50–3. / Mychka V.B., Zhernakova Yu.V., Chazova I.E. The improved form perindopril in treatment of arterial hypertension in various clinical situations (PREMIA). Systemic Hypertension. 2009; 6 (4): 50–3. [in Russian]
18. Морозова Т.Е., Латыйпова Е.Р. Больной АГ с ожирением: влияние на биомаркеры как инструмент персонализированного подхода к терапии. Рос. кардиол. журн. 2013; 3 (101): 94–9. / Morozova T.E., Latyipova E.R. Bol'noi AG s ozhireniem: vliianie na biomarkery kak instrument personalizirovannogo podkhoda k terapii. Ros. kardiol. zhurn. 2013; 3 (101): 94–9. [in Russian]
19. Морозова Т.Е., Гонтаренко С.В. Влияние антигипертензивных препаратов на состояние когнитивных функций у больных артериальной гипертензией I–II степени. Лечащий врач. 2014; 7: 15–20. / Morozova T.E., Gontarenko S.V. Vliianie antigipertenzivnykh preparatov na sostoianie kognitivnykh funktsii u bol'nykh arterial'noi gipertenziei I–II stepeni. Lechashchii vrach. 2014; 7: 15–20. [in Russian]
20. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association. American Stroke Association. Stroke 2011; 42: 227–76.
21. Nice guidelines. Management of hypertension in adults in primary care. Update of clinical guidelines 18 and 34, 2011. http://www.nice.org.uk
22. Leonetti G, Rappelli A, Salvetti A et al. Long-term effects of indapamide: final results of a two-year Italian multicenter study in systemic hypertension. Am J Cardiol 1990; 65: 67–71.
23. Harrower A, McFarlane G, Donnelly T et al. Effect of indapamide on blood pressure and glucose tolerance in non-insulin-dependent diabetes. Hypertension 1985; 7 (Suppl. II): 161–3.
24. Mironneau J. Indapamide-induced inhibition of calcium movement in smooth muscles. Am J Med 1988; 84 (Suppl. IB): 10–4.
25. Schini VB, Dewey J, Vanhoutte PM. Related effects of indapamide on endothelium – dependent relaxations in isolated canine femoral arteries. Am J Cardiol 1990; 65: H6–10.
26. Gosse PH, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus Enalapril 20 mg: LIVE study. J Hypertens 2000; 18: 1465–75.
27. Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study. Vasc Health Risk Manag 2008; 4 (2): 443–51.
28. Pella D. Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg: results of the FALCO FORTE programme. High Blood Press Cardiovasc Prev 2011; 18 (3): 107–13.
29. Dahlof B, Grosse P, Gueret P et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PIXEL study. J Hypertension 2005; 23: 2063–70.
30. Mogensen CE, Viberti G, Halimi S et al. Preterax in Albuminuria Regression (PREMIER) Study Groupe. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Preterax in Albuminuria Regression: PREMIER. Hypertension 2003; 41: 1063–71.
31. Zoungas S et al. Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. N Engl J Med. Doi: 10.1056/NEJMoa1407963.
32. Чазова И., Ратова Л., Мартынюк Т. от имени коллектива авторов. Итоги Российского исследования СТРАТЕГИЯ А (Российская многоцентровая программа по оценке эффективности Нолипрела А Форте у пациентов с артериальной гипертонией высокого риска с недостаточным контролем артериального давления). Consilium Medicum. 2012; 14 (1): 5–12. / Chazova I., Ratova L., Martyniuk T. ot imeni kollektiva avtorov. Itogi Rossiiskogo issledovaniia STRATEGIIa A (Rossiiskaia mnogotsentrovaia programma po otsenke effektivnosti Noliprela A Forte u patsientov s arterial'noi gipertoniei vysokogo riska s nedostatochnym kontrolem arterial'nogo davleniia). Consilium Medicum. 2012; 14 (1): 5–12. [in Russian]
33. Маньковский Б.Н., Иванов Д.Д. Влияние антигипертензивной терапии на функцию почек у больных сахарным диабетом 2 типа: результаты проспективного исследования СКИФ-2. ProCardio 2010; 8 (144): 28–32. / Man'kovskii B.N., Ivanov D.D. Vliianie antigipertenzivnoi terapii na funktsiiu pochek u bol'nykh sakharnym diabetom 2 tipa: rezul'taty prospektivnogo issledovaniia SKIF-2. ProCardio 2010; 8 (144): 28–32. [in Russian]
34. Сиренко Ю.Н., Маньковский Б.Н., Радченко А.Д., Кушнир С.Н. от имени участников исследования. Результаты проспективного открытого исследования по оценке антигипертензивной эффективности и переносимости нолипрела би-форте у пациентов с неконтролируемой артериальной гипертензией и сахарным диабетом 2-го типа (исследованиe практик). Артериальная гипертензия. 2012; 4 (24): 9–23. / Sirenko Iu.N., Man'kovskii B.N., Radchenko A.D., Kushnir S.N. ot imeni uchastnikov issledovaniia. Rezul'taty prospektivnogo otkrytogo issledovaniia po otsenke antigipertenzivnoi effektivnosti i perenosimosti noliprela bi-forte u patsientov s nekontroliruemoi arterial'noi gipertenziei i sakharnym diabetom 2-go tipa (issledovanie praktik). Arterial'naia gipertenziia. 2012; 4 (24): 9–23. [in Russian]
35. De Galan BE, Perkovic V, Ninomiya T et al. On behalfof the ADVANCE Collaborativе Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrology 2009. Doi: 10.1681/ASN.2008070667.9, 20.
36. Ruilope LM, Mancia G, Chalmers J. Does use of antihypertensive treatment to reduce albuminuria translate into effective benefits on outcome and mortality? A reappraisal of studies with renal endpoints in diabetes. J Hypertens 2010; 28. Doi: 10.1097/01.hjh.0000379031.35224.c0.
37. Глезер М.Г., Авакян А.А. Эффективность и безопасность терапии полнодозовой комбинацией периндоприла А/индапамида (10/2,5 мг) у пациентов с артериальной гипертонией. Кардиоваск. профилактика и терапия. 2012; 5: 4–11. / Glezer M.G., Avakian A.A. Effektivnost' i bezopasnost' terapii polnodozovoi kombinatsiei perindoprila A/indapamida (10/2,5 mg) u patsientov s arterial'noi gipertoniei. Kardiovask. profilaktika i terapiia. 2012; 5: 4–11. [in Russian]
38. Карпов Ю.А. Программа ФОРТИССИМО: преимущества фиксированной полнодозовой комбинации периндоприла аргинина и индапамида в лечении плохо контролируемой артериальной гипертонии от имени участников программы ФОРТИССИМО. Кардиология. 2013; 3: 37–43. / Karpov Iu.A. Programma FORTISSIMO: preimushchestva fiksirovannoi polnodozovoi kombinatsii perindoprila arginina i indapamida v lechenii plokho kontroliruemoi arterial'noi gipertonii ot imeni uchastnikov programmy FORTISSIMO. Kardiologiia. 2013; 3: 37–43. [in Russian]
________________________________________________
2. Recommendations for the management of arterial hypertension Russian Medical Society of Arterial Hypertension and Society of Cardiology of the Russian Federation. Systemic Hypertension. 2010; 7 (3). [in Russian]
3. ESH/ESC Guidelines for themanagement of arterial hypertension. J Hypertens 2013; 31: 1281–357.
4. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
5. Wald DS et al. Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials. Am J Med 2009; 122 (3): 290.
6. Leonova M.V., Belousov D.Iu., Shteinberg L.L. i analiticheskaia gruppa issledovaniia PIFAGOR. Analiz vrachebnoi praktiki provedeniia antigipertenzivnoi terapii v Rossii (po dannym issledovaniia PIFAGOR III). Farmateka. 2009; 2: 98–103. [in Russian]
7. The PROGRESS Collaborative Group. Randomised trial of aperindopril-based blood-pressure-lowering among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
8. The EUROPA investigators. Efficacy of perindopril in reduction ofcardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentertrial (the EUROPA study). Lancet 2003; 362: 782–8.
9. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascularevents with an antihypertensive regimen of amlodipine adding perindopril as required vs. atenolol adding bendroflumethiazide asrequired, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
10. Beckett NS, Peters R, Fletcher AE et al for the HYVET Study Group. Treatment of hypertension in patients 80 years of age and older. NEJM 2008; 358: 1887–98.
11. ADVANCE Collaborative Group. Effects of fixed combination ofperindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial):a randomised controlled trial. Lancet 2007; 370: 828–40.
12. Vark van LC, Bertrand M, Akkerhuis KM et al. Angiotensin-convertingenzyme inhibitors reduce mortality in hypertension: a metaanalysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012; 33 (16): 2088–97.
13. Romanenko V.V., Romanenko Z.V. Ingibitory APF – preparaty pervoi linii v lechenii serdechno-sosudistykh zabolevanii. Mezhdunarodnye obzory: klinicheskaia praktika i zdorov'e. 2014; 3 (9): 5–25. [in Russian]
14. Brugts JJ, Arima H, Remme W et al. The Incidence and Clinical predictors of ACE inhibitor Induced Dry Cough by Perindopril in 27.492 Patients with Vascular Disease: A Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS-trials comparing a perindopril-treatment regimen versus placebo. Int J Cardiol 2014. Doi: 10.1016/j.ijcard. 2014.07.108.
15. Daly CA, Fox KM, Remme WJ. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26: 1369–78.
16. Dufouil C, Chalmers J, Coskun O. Effects of blood pressure lowering of cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112 (11): 1644–50.
17. Mychka V.B., Zhernakova Yu.V., Chazova I.E. The improved form perindopril in treatment of arterial hypertension in various clinical situations (PREMIA). Systemic Hypertension. 2009; 6 (4): 50–3. [in Russian]
18. Morozova T.E., Latyipova E.R. Bol'noi AG s ozhireniem: vliianie na biomarkery kak instrument personalizirovannogo podkhoda k terapii. Ros. kardiol. zhurn. 2013; 3 (101): 94–9. [in Russian]
19. Morozova T.E., Gontarenko S.V. Vliianie antigipertenzivnykh preparatov na sostoianie kognitivnykh funktsii u bol'nykh arterial'noi gipertenziei I–II stepeni. Lechashchii vrach. 2014; 7: 15–20. [in Russian]
20. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association. American Stroke Association. Stroke 2011; 42: 227–76.
21. Nice guidelines. Management of hypertension in adults in primary care. Update of clinical guidelines 18 and 34, 2011. http://www.nice.org.uk
22. Leonetti G, Rappelli A, Salvetti A et al. Long-term effects of indapamide: final results of a two-year Italian multicenter study in systemic hypertension. Am J Cardiol 1990; 65: 67–71.
23. Harrower A, McFarlane G, Donnelly T et al. Effect of indapamide on blood pressure and glucose tolerance in non-insulin-dependent diabetes. Hypertension 1985; 7 (Suppl. II): 161–3.
24. Mironneau J. Indapamide-induced inhibition of calcium movement in smooth muscles. Am J Med 1988; 84 (Suppl. IB): 10–4.
25. Schini VB, Dewey J, Vanhoutte PM. Related effects of indapamide on endothelium – dependent relaxations in isolated canine femoral arteries. Am J Cardiol 1990; 65: H6–10.
26. Gosse PH, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus Enalapril 20 mg: LIVE study. J Hypertens 2000; 18: 1465–75.
27. Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study. Vasc Health Risk Manag 2008; 4 (2): 443–51.
28. Pella D. Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg: results of the FALCO FORTE programme. High Blood Press Cardiovasc Prev 2011; 18 (3): 107–13.
29. Dahlof B, Grosse P, Gueret P et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PIXEL study. J Hypertension 2005; 23: 2063–70.
30. Mogensen CE, Viberti G, Halimi S et al. Preterax in Albuminuria Regression (PREMIER) Study Groupe. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Preterax in Albuminuria Regression: PREMIER. Hypertension 2003; 41: 1063–71.
31. Zoungas S et al. Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. N Engl J Med. Doi: 10.1056/NEJMoa1407963.
32. Chazova I., Ratova L., Martyniuk T. ot imeni kollektiva avtorov. Itogi Rossiiskogo issledovaniia STRATEGIIa A (Rossiiskaia mnogotsentrovaia programma po otsenke effektivnosti Noliprela A Forte u patsientov s arterial'noi gipertoniei vysokogo riska s nedostatochnym kontrolem arterial'nogo davleniia). Consilium Medicum. 2012; 14 (1): 5–12. [in Russian]
33. Man'kovskii B.N., Ivanov D.D. Vliianie antigipertenzivnoi terapii na funktsiiu pochek u bol'nykh sakharnym diabetom 2 tipa: rezul'taty prospektivnogo issledovaniia SKIF-2. ProCardio 2010; 8 (144): 28–32. [in Russian]
34. Sirenko Iu.N., Man'kovskii B.N., Radchenko A.D., Kushnir S.N. ot imeni uchastnikov issledovaniia. Rezul'taty prospektivnogo otkrytogo issledovaniia po otsenke antigipertenzivnoi effektivnosti i perenosimosti noliprela bi-forte u patsientov s nekontroliruemoi arterial'noi gipertenziei i sakharnym diabetom 2-go tipa (issledovanie praktik). Arterial'naia gipertenziia. 2012; 4 (24): 9–23. [in Russian]
35. De Galan BE, Perkovic V, Ninomiya T et al. On behalfof the ADVANCE Collaborativе Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrology 2009. Doi: 10.1681/ASN.2008070667.9, 20.
36. Ruilope LM, Mancia G, Chalmers J. Does use of antihypertensive treatment to reduce albuminuria translate into effective benefits on outcome and mortality? A reappraisal of studies with renal endpoints in diabetes. J Hypertens 2010; 28. Doi: 10.1097/01.hjh.0000379031.35224.c0.
37. Glezer M.G., Avakian A.A. Effektivnost' i bezopasnost' terapii polnodozovoi kombinatsiei perindoprila A/indapamida (10/2,5 mg) u patsientov s arterial'noi gipertoniei. Kardiovask. profilaktika i terapiia. 2012; 5: 4–11. [in Russian]
38. Karpov Iu.A. Programma FORTISSIMO: preimushchestva fiksirovannoi polnodozovoi kombinatsii perindoprila arginina i indapamida v lechenii plokho kontroliruemoi arterial'noi gipertonii ot imeni uchastnikov programmy FORTISSIMO. Kardiologiia. 2013; 3: 37–43. [in Russian]
Авторы
Т.Е.Морозова*, С.В.Гонтаренко
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*temorozova@gmail.com
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*temorozova@gmail.com
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*temorozova@gmail.com
________________________________________________
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*temorozova@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.